How CVS Has Traded Around Earnings
CVS Health has beaten earnings estimates in 7 of the last 8 reported quarters, an 88% beat rate, with an average earnings surprise of 14%. That means the headline result has historically landed above the published consensus by a meaningful margin. Looking at the four most recent reports, the beats were 17.9% on May 6, 2026 ($2.57 actual vs. $2.18 estimate), 9% on February 10, 2026 ($1.09 vs. $1.00), 16.8% on October 29, 2025 ($1.60 vs. $1.37), and 24% on July 31, 2025 ($1.81 vs. $1.46).
Yet the next-day stock reaction has not always matched the headline beat. Those same four reports produced one-day moves of 0.58%, 1.85%, -4.85%, and 0.6%. The 5-day post-earnings drift, however, has been more consistently positive: the same quarters saw 5-day returns of 12.95%, 2.82%, -2.54%, and 2.38%, and the average 5-day move across the last eight quarters is 3.9% higher. That gap between the immediate reaction and the following-week drift is the central trading rhythm for this Healthcare/Medical - Healthcare Plans name.
Options-Flow Dynamics for the 2026-08-05 Report
CVS is scheduled to report next on August 5, 2026, before the market opens, with a published consensus EPS estimate of $1.87. With the stock at $107.47 and the 50-day EMA at $97.96, price has already moved well above its intermediate moving average. The RSI is 68.2, which puts the name inside the commonly watched upper-reach zone that can both attract momentum and warn of a crowded long setup.
Into the report, options flow typically reflects two competing forces: premium buyers positioning for the 3.9% average 5-day post-earnings drift, and hedgers trying to cap downside in case the real expectation — the unofficial consensus embedded in desk chatter and order flow — is not met. Expect implied volatility to rise ahead of the print and then compress once the event passes. A useful comparison is the options-implied move for the first trading day versus the actual one-day and five-day realized moves above. The last four next-day observations ranged from -4.85% to +1.85%, so a straddle priced near that band is not automatically cheap or expensive; it depends on how much realized volatility survives the typical post-print implied-volatility crush.
What a Disciplined Trader Watches Around CVS Reports
History shows that beating estimates is not the same as rallying the next session. A 14% average surprise has historically been the norm, but the market reprices based on guidance, forward-year commentary, and the unofficial consensus rather than the EPS number alone. A disciplined approach starts by comparing the upcoming $1.87 estimate with the market's real expectation, then tracking whether the options market is pricing a move that is larger or smaller than the historical 5-day realized drift.
Watch the price action relative to the $97.96 50-day EMA: a gap above or below that level after the report can frame whether institutions are treating the print as a continuation of the prevailing trend or as a reversal. Also watch for post-earnings implied-volatility crush; if the stock fails to move enough to cover the premium paid, even a correct directional view can lose money. Finally, keep the distribution of historical outcomes in mind: the last four next-day moves ranged from -4.85% to +1.85%, and the 5-day outcomes ranged from -2.54% to +12.95%. That range argues for position sizing that survives either tail, rather than a directional bet sized for the average outcome.
For a deeper dive into the data behind this setup, view the full institutional verdict on CVS. It aggregates analyst rating distributions, recent target changes, and post-earnings flow context so you can place this historical pattern into the current consensus picture.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-05-06 | $2.57 | $2.18 | +17.9% | +0.58% | +12.95% |
| 2026-02-10 | $1.09 | $1 | +9% | +1.85% | +2.82% |
| 2025-10-29 | $1.6 | $1.37 | +16.8% | -4.85% | -2.54% |
| 2025-07-31 | $1.81 | $1.46 | +24% | +0.6% | +2.38% |
| 2025-05-01 | $2.25 | $1.7 | +32.4% | - | - |
| 2025-02-12 | $1.19 | $0.914 | +30.2% | - | - |
Get the institutional verdict on CVS
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the CVS verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.